IRLAB Therapeutics Future Growth
Future criteria checks 5/6
IRLAB Therapeutics is forecast to grow earnings and revenue by 23.5% and 31.3% per annum respectively. EPS is expected to grow by 4.8% per annum. Return on equity is forecast to be -22.1% in 3 years.
Key information
23.5%
Earnings growth rate
4.8%
EPS growth rate
| Pharmaceuticals earnings growth | 75.2% |
| Revenue growth rate | 31.3% |
| Future return on equity | -22.1% |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?
Oct 30
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 89 | -116 | -116 | -116 | 1 |
| 12/31/2025 | 222 | 156 | 159 | 159 | 2 |
| 12/31/2024 | 132 | -58 | -17 | -17 | 3 |
| 9/30/2024 | 51 | -113 | -77 | -77 | N/A |
| 6/30/2024 | 42 | -119 | -109 | -109 | N/A |
| 3/31/2024 | 6 | -157 | -162 | -162 | N/A |
| 12/31/2023 | 6 | -178 | -165 | -165 | N/A |
| 9/30/2023 | 19 | -176 | -169 | -169 | N/A |
| 6/30/2023 | 36 | -162 | -163 | -160 | N/A |
| 3/31/2023 | 52 | -144 | -155 | -151 | N/A |
| 12/31/2022 | 61 | -113 | -146 | -143 | N/A |
| 9/30/2022 | 61 | -103 | -136 | -133 | N/A |
| 6/30/2022 | 240 | 42 | 96 | 98 | N/A |
| 3/31/2022 | 217 | 43 | 117 | 118 | N/A |
| 12/31/2021 | 208 | 52 | 128 | 129 | N/A |
| 9/30/2021 | 196 | 55 | 140 | 141 | N/A |
| 6/30/2021 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2021 | N/A | -93 | -88 | -87 | N/A |
| 12/31/2020 | 0 | -92 | -90 | -89 | N/A |
| 9/30/2020 | 0 | -99 | -99 | -99 | N/A |
| 6/30/2020 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2020 | 1 | -98 | -98 | -98 | N/A |
| 12/31/2019 | 0 | -96 | -91 | -91 | N/A |
| 9/30/2019 | 1 | -88 | -83 | -83 | N/A |
| 6/30/2019 | 1 | -83 | -78 | -78 | N/A |
| 3/31/2019 | 0 | -76 | -75 | -75 | N/A |
| 12/31/2018 | 0 | -74 | -72 | -71 | N/A |
| 9/30/2018 | 0 | -68 | -76 | -75 | N/A |
| 6/30/2018 | 0 | -73 | N/A | -67 | N/A |
| 3/31/2018 | 0 | -60 | N/A | -58 | N/A |
| 12/31/2017 | 0 | -56 | N/A | -58 | N/A |
| 9/30/2017 | 0 | -58 | N/A | -48 | N/A |
| 6/30/2017 | 0 | -48 | N/A | -45 | N/A |
| 3/31/2017 | 3 | -44 | N/A | -45 | N/A |
| 12/31/2016 | 3 | -43 | N/A | -41 | N/A |
| 12/31/2015 | 3 | -12 | N/A | -28 | N/A |
| 12/31/2014 | 3 | 3 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRLAB A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: IRLAB A is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IRLAB A is expected to become profitable in the next 3 years.
Revenue vs Market: IRLAB A's revenue (31.3% per year) is forecast to grow faster than the Swedish market (1.2% per year).
High Growth Revenue: IRLAB A's revenue (31.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IRLAB A is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 09:13 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IRLAB Therapeutics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gonzalo Artiach Castanon | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |
| Soo Romanoff | Edison Investment Research |